Menu
Analysis guide 2022-09-12
Peptonic Medical increased sales by 13% in H1 2022 to SEK 21.3 million. The new strategy of clinically proven self-care following the diagnose-treat-prevention principle meets a strong societal trend that is reflected in growing sales and a strong order backlog. The company is in an expansion phase and is expected to be profitable from 2025. As the company communicated in its Q1 report, there are additional future financing needs.
Analysis guide 2019-06-10
Peptonic is carrying out a new share issue to further invest in VagiVital®. The market presence in Sweden has been strengthened and customer satisfaction is high. Further establishment in the Nordic region is at the top of the agenda, but the US may become relevant as early as the end of 2020.
Analysis guide 2018-04-27
Peptonic carries out an emission before the launch of VagiVital®. The money should also be enough for marketing costs in Sweden. With clinical data demonstrating the product’s good effect, it is not unreasonable that VagiVital® can quickly gain market share, given that the launch will take place as planned.
Analysis guide 2017-06-02
Peptonic’s failed phase II studies support the launch of an over-the-counter self-care product for vaginal atrophy. The road to the market is shorter and less risky. A launch could take place as early as in 2018. We recommend Teckna.
Analysis guide 2016-06-22
Big upside but high risk. Peptonic’s ongoing phase IIb study is progressing as planned. The study results are expected to be in place in December and are crucial for the company as well as for the share. In the case of positive results, the upside is great.
Analysis guide 2016-03-08
With a higher cash flow, Peptonic intends to once again take its drug candidate Vagitocin® to the clinics. The company has presented an agenda for the study with an estimated schedule.
